Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
Saved in:
| Title: | Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study. |
|---|---|
| Authors: | Fricke JG; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Westerbergh F; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden., McDougall L; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Favaretto C; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Christ E; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.; Division of Endocrinology, University Hospital Basel, Basel, Switzerland., Nicolas GP; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland., Geistlich S; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Schmid DE; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Borgna F; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland., Fani M; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., Bernhardt P; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.; Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden., van der Meulen NP; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, Switzerland; and., Müller C; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Wild D; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; damian.wild@usb.ch.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2026 Mar 02; Vol. 67 (3), pp. 416-422. Date of Electronic Publication: 2026 Mar 02. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
